The global burden of chronic pain and the ongoing opioid crisis have renewed scientific interest in plant-derived analgesics as complementary or alternative therapeutic strategies. This comprehensive review examines the pharmacological evidence supporting the use of phytochemicals in pain management, with emphasis on molecular mechanisms, preclinical and clinical efficacy, and translational potential. Major themes include the identification of bioactive constituents such as alkaloids, terpenoids, flavonoids, and phenolic compounds that modulate nociceptive pathways through diverse mechanisms including cyclooxygenase inhibition, transient receptor potential channel modulation, endocannabinoid system activation, and neuroimmune regulation. Preclinical studies in cellular and animal models have demonstrated dose-dependent analgesic effects across multiple pain paradigms, while clinical trials provide preliminary evidence of efficacy in conditions ranging from osteoarthritis to neuropathic pain. Pharmacokinetic considerations including bioavailability enhancement, formulation optimization, and metabolic interactions are critical for translating botanical compounds into standardized therapeutics. Safety profiles generally favor plant-based analgesics over conventional opioids, though herb-drug interactions and quality control challenges necessitate rigorous standardization and regulatory oversight. The opioid-sparing potential of phytochemicals represents a significant opportunity to reduce dependence on synthetic narcotics while maintaining adequate pain control. Future directions include development of novel delivery systems, standardized extracts with defined phytochemical ratios, combination therapies, and precision phytotherapy guided by pharmacogenomic profiling. Integration of traditional ethnopharmacological knowledge with modern pharmaceutical sciences promises to expand the therapeutic armamentarium for pain management.